Veozah: payments to doctors
Payments that named Veozah as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $12.3M
- Providers
- 68,399
- Transactions
- 248,059
- Average per transaction
- $50
The per-transaction average — $50 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 68,399 providers the average total is $180, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $11,937,854 | 97.1% |
| Astellas Pharma Global Development | $249,255 | 2.0% |
| Astellas Pharma Europe Ltd | $100,614 | 0.8% |
| Astellas US LLC | $7,200 | 0.1% |